We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aphton announced positive results from an open-label dose-escalating Phase I
trial with IGN311, a humanized monoclonal antibody targeting the Lewis Y tumor-associated
antigen.
Millennium Pharmaceuticals announced the initiation of a multicenter Phase II
clinical trial of MLN1202 in approximately 40 patients with relapsing-remitting
multiple sclerosis (MS), the most common form of the disease.
Durect announced the start of dosing in the third and final cohort of the Phase
II dose escalation study in hernia patients in Australia for Durect's postoperative
pain relief depot, Saber-Bupivacaine.
Dynavax Technologies announced that enrollment in the company's clinical trial
of its AIC (Amb a 1 immunostimulatory conjugate) ragweed allergy immunotherapy
in ragweed allergic children has exceeded expectations relative to speed of
enrollment and number of study subjects.
InterMune, announced the completion of patient enrollment in its Phase III clinical
trial of daily Infergen in combination with ribavirin for the treatment of patients
chronically infected with hepatitis C virus (HCV) who have failed to respond
to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin.
Maxim Pharmaceuticals has been issued a U.S. patent 6,906,203, titled "Substituted
4H-Chromene and Analogs as Activators of Caspases and Inducers of Apoptosis
and the Use Thereof.
The FDA has accepted for filing and review OSI's supplemental new drug application
(sNDA) for use of Tarceva plus gemcitabine chemotherapy for the treatment of
advanced pancreatic cancer in patients who have not received previous treatment.
QLT has announced that it has received final approval from the FDA
to market Aczone (dapsone) Gel, 5 percent for the topical treatment of acne
vulgaris.
Par has received FDA approval for Megace ES, a concentrated oral suspension
for the treatment of anorexia, cachexia or an unexplained, significant weight
loss in patients with a diagnosis of AIDS.